DarioHealth Seeks Reverse Stock Split, Board Re-election
Ticker: DRIO · Form: DEF 14A · Filed: May 30, 2025 · CIK: 1533998
| Field | Detail |
|---|---|
| Company | Dariohealth CORP. (DRIO) |
| Form Type | DEF 14A |
| Filed Date | May 30, 2025 |
| Risk Level | medium |
| Sentiment | mixed |
Sentiment: mixed
Topics: Proxy Statement, Reverse Stock Split, Board Re-election, Equity Compensation Plan, Corporate Governance, Shareholder Meeting, Auditor Ratification
Related Tickers: DRIO
TL;DR
**DRIO is pushing a reverse stock split, signaling a desperate move to prop up its share price and avoid delisting; tread carefully.**
AI Summary
DarioHealth Corp. (DRIO) filed a DEF 14A on May 30, 2025, outlining proposals for its Annual Meeting on July 23, 2025. Key proposals include the re-election of seven directors: Hila Karah, Dennis Matheis, Dennis M. McGrath, Erez Raphael, Yoav Shaked, Lawrence Leisure, and Adam K. Stern. The company also seeks to ratify Kesselman & Kesselman, a member of PricewaterhouseCoopers International Limited, as its independent registered public accounting firm for the fiscal year ending December 31, 2025. A significant proposal involves amending and restating the Company's 2020 Equity Compensation Plan. Furthermore, the Board is seeking authorization to amend the Certificate of Incorporation to effect a reverse stock split of common stock at a ratio of not less than two (2) to one. This reverse stock split, if approved, aims to increase the per-share trading price, potentially to maintain listing requirements or attract institutional investors. The filing does not contain specific revenue or net income figures, focusing instead on governance and corporate actions.
Why It Matters
DarioHealth's proposed reverse stock split, at a ratio of not less than 2-to-1, is a critical move for investors, potentially signaling efforts to boost share price and maintain exchange listing compliance, which could impact liquidity and investor confidence. For employees, the amendment to the 2020 Equity Compensation Plan could alter the value and structure of their stock-based incentives. Customers are less directly impacted by these governance changes, but a stronger financial position could enable continued investment in product development. In the competitive digital health market, a higher stock price might improve DRIO's perceived stability and attractiveness compared to rivals.
Risk Assessment
Risk Level: medium — The proposal to authorize a reverse stock split at a ratio of not less than two (2) to one indicates potential concerns about the company's stock price, which often precedes delisting warnings or struggles to attract institutional investment. While not explicitly stated as a delisting cure, this action is frequently taken by companies with low share prices, suggesting underlying financial or market performance challenges. The lack of specific financial performance data in this DEF 14A also contributes to a medium risk assessment.
Analyst Insight
Investors should closely monitor the outcome of the reverse stock split vote and understand its implications for share value and market perception. Evaluate DarioHealth's underlying financials and competitive position before making any investment decisions, as a reverse split alone does not guarantee long-term value creation.
Key Numbers
- 2025-05-30 — Filing Date (Date DEF 14A was filed by DarioHealth Corp.)
- 2025-07-23 — Annual Meeting Date (Date of DarioHealth Corp.'s Annual Meeting of Stockholders)
- 7 — Number of Directors (Number of directors proposed for re-election to the Board)
- 2020 — Equity Compensation Plan Year (Year of the Equity Compensation Plan proposed for amendment and restatement)
- 2 — Reverse Stock Split Ratio (minimum) (Minimum ratio for the proposed reverse stock split (2-to-1))
- $0.0001 — Common Stock Par Value (Par value per share of DarioHealth Corp.'s common stock)
Key Players & Entities
- DarioHealth Corp. (company) — Registrant filing DEF 14A
- Hila Karah (person) — Director nominee for re-election
- Dennis Matheis (person) — Director nominee for re-election
- Dennis M. McGrath (person) — Director nominee for re-election
- Erez Raphael (person) — Director nominee for re-election
- Yoav Shaked (person) — Director nominee for re-election
- Lawrence Leisure (person) — Director nominee for re-election
- Adam K. Stern (person) — Director nominee for re-election
- Kesselman & Kesselman (company) — Proposed independent registered public accounting firm
- PricewaterhouseCoopers International Limited (company) — Member firm of proposed accounting firm
FAQ
What is DarioHealth Corp.'s primary business?
DarioHealth Corp. operates in the Surgical & Medical Instruments & Apparatus industry, SIC code 3841, focusing on digital health solutions. The company's offerings typically involve connected devices and software for managing chronic conditions.
When is DarioHealth Corp.'s Annual Meeting of Stockholders?
DarioHealth Corp.'s Annual Meeting of Stockholders is scheduled for Wednesday, July 23, 2025, at 4:00 p.m. Israel Time, at their Israeli office located at 5 Tarshish St., 2nd Floor, Caesarea Industrial Park, 3088900, Israel.
What are the key proposals for DarioHealth Corp.'s 2025 Annual Meeting?
The key proposals for DarioHealth Corp.'s 2025 Annual Meeting include the re-election of seven directors, ratification of Kesselman & Kesselman as the independent auditor for fiscal year 2025, amendment and restatement of the 2020 Equity Compensation Plan, and authorization for a reverse stock split of common stock at a ratio of not less than two (2) to one.
Who are the directors proposed for re-election at DarioHealth Corp.?
The directors proposed for re-election to DarioHealth Corp.'s Board are Hila Karah, Dennis Matheis, Dennis M. McGrath, Erez Raphael, Yoav Shaked, Lawrence Leisure, and Adam K. Stern. They are proposed to serve a one-year term expiring at the 2026 Annual Meeting.
Which accounting firm is DarioHealth Corp. proposing to ratify for 2025?
DarioHealth Corp. is proposing to ratify the appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Limited, as its independent registered public accounting firm for the fiscal year ending December 31, 2025.
What is the purpose of amending DarioHealth Corp.'s 2020 Equity Compensation Plan?
The DEF 14A states that stockholders will consider and vote to amend and restate the Company's 2020 Equity Compensation Plan, as amended. This typically involves updating terms, share reserves, or eligibility criteria to align with current compensation strategies and market practices.
Why is DarioHealth Corp. proposing a reverse stock split?
DarioHealth Corp. is seeking authorization to effect a reverse stock split of its common stock at a ratio of not less than two (2) to one. This action is commonly undertaken to increase the per-share trading price, potentially to meet exchange listing requirements, improve marketability, or attract a broader base of institutional investors.
What is the par value of DarioHealth Corp.'s common stock?
The par value of DarioHealth Corp.'s issued and outstanding shares of common stock is $0.0001 per share, as stated in the DEF 14A filing.
Where is DarioHealth Corp.'s business address?
DarioHealth Corp.'s business address is 322 W 57th St. #33B, New York, NY 10019. Their Israeli office, where the annual meeting will be held, is at 5 Tarshish St., 2nd Floor, Caesarea Industrial Park, 3088900, Israel.
What is the potential impact of a reverse stock split on DarioHealth Corp. investors?
A reverse stock split will reduce the number of outstanding shares and proportionally increase the price per share, but it does not change the total market capitalization or the intrinsic value of an investor's holdings immediately. Investors will own fewer shares, but each share will be worth more, potentially improving liquidity and meeting listing requirements, though it can also be perceived negatively by the market.
Industry Context
DarioHealth Corp. operates in the medical devices and digital health sector, which is characterized by rapid technological advancements, increasing regulatory scrutiny, and a competitive landscape with both established players and emerging startups. The industry is driven by the demand for innovative solutions in remote patient monitoring, chronic disease management, and personalized healthcare.
Regulatory Implications
The proposed reverse stock split could be driven by a need to maintain compliance with stock exchange listing requirements, which often have minimum bid price thresholds. Failure to meet these requirements could lead to delisting, impacting liquidity and investor confidence. The amendment of the equity compensation plan also falls under regulatory oversight concerning executive compensation disclosure and shareholder approval.
What Investors Should Do
- Review the proposals for the Annual Meeting
- Understand the rationale and implications of the reverse stock split
- Evaluate the proposed changes to the Equity Compensation Plan
Key Dates
- 2025-05-30: Filing of Definitive Proxy Statement (DEF 14A) — Provides shareholders with information regarding the annual meeting agenda, director nominations, auditor ratification, and corporate actions like equity plan amendments and a potential reverse stock split.
- 2025-07-23: Annual Meeting of Stockholders — Shareholders will vote on key proposals including director re-elections, ratification of the independent auditor, amendment of the equity compensation plan, and authorization for a reverse stock split.
- 2025-12-31: Fiscal Year End — The independent registered public accounting firm is being appointed to audit the company's financial statements for this fiscal year.
Glossary
- DEF 14A
- A Definitive Proxy Statement filed with the SEC by a company to solicit shareholder votes for its annual meeting. (This filing outlines the proposals shareholders will vote on at DarioHealth Corp.'s annual meeting.)
- Reverse Stock Split
- A corporate action where a company reduces the number of its outstanding shares by consolidating them into fewer, proportionally more valuable shares. (DarioHealth Corp. is seeking authorization to implement a reverse stock split, aiming to increase its per-share trading price.)
- Equity Compensation Plan
- A plan established by a company to grant stock options, restricted stock, or other equity-based awards to employees, directors, or consultants. (The company is proposing to amend and restate its 2020 Equity Compensation Plan, which could affect future executive and employee compensation.)
- Independent Registered Public Accounting Firm
- An external audit firm hired by a company's audit committee to provide an independent opinion on the fairness of the company's financial statements. (Kesselman & Kesselman is proposed for ratification as DarioHealth Corp.'s auditor for the fiscal year ending December 31, 2025.)
- Certificate of Incorporation
- The foundational legal document filed with the state of incorporation that creates a corporation. (The company seeks authorization to amend its Certificate of Incorporation to effect the reverse stock split.)
Year-Over-Year Comparison
This filing is a DEF 14A, which focuses on corporate governance and upcoming shareholder votes rather than a direct comparison of financial performance metrics to a prior period. Unlike an annual report (10-K) or a quarterly report (10-Q), it does not contain detailed financial statements or year-over-year performance comparisons. The key information relates to proposed corporate actions for the upcoming annual meeting.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on May 30, 2025 by Hila Karah regarding DarioHealth Corp. (DRIO).